19
ALL6
Cassiopea7
Cosmo Pharmaceuticals1
Curia1
Glenmark Pharmaceuticals4
Sun Pharmaceutical Industries LimitedYear
19
ALL1
20251
20247
20235
20222
20213
2020DEALS // DEV.
19
ALL10
Deals9
DevelopmentsCountry
19
ALL5
INDIA7
IRELAND6
ITALY1
U.S.A19
ALL1
3S Bio Inc2
Cassiopea3
Cosmo Pharmaceuticals1
Glenmark Pharmaceuticals1
Hikma Pharmaceuticals1
Hyphens Pharma1
Hyundai Pharm1
InfectoPharm Drugs and Consilium6
Not Applicable2
Sun Pharmaceutical Industries LimitedTherapeutic Area
19
ALL19
DermatologyStudy Phase
19
ALL1
Approved FDF18
ApprovedDeal Type
11
ALL1
Acquisition1
Agreement1
Inapplicable8
Licensing AgreementProduct Type
19
ALL18
Small molecule1
SteroidDosage Form
11
ALL5
Cream6
Topical CreamLead Product
19
ALL19
ClascoteroneTarget
7
ALL7
Androgen receptorLead Product(s) : Clascoterone
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Cosmo Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Glenmark, Cosmo get MHRA Nod to Market Acne Treatment Medication in UK
Details : Winlevi (clascoterone) cream is a prescription medicine and an androgen receptor antagonist, used on the skin (topical) to treat acne vulgaris in people 12 years of age and older.
Product Name : Winlevi
Product Type : Steroid
Upfront Cash : Inapplicable
February 10, 2025
Lead Product(s) : Clascoterone
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Cosmo Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clascoterone
Therapeutic Area : Dermatology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Sun Pharmaceuticals Receives Approval for Winlevi in Australia
Details : Winlevi (clascoterone) cream is an androgen receptor inhibitor recently approved by the TGA for commercialization in Australia, indicated for treating acne vulgaris in patients 12 and older.
Product Name : Winlevi
Product Type : Small molecule
Upfront Cash : Not Applicable
March 20, 2024
Lead Product(s) : Clascoterone
Therapeutic Area : Dermatology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Clascoterone
Therapeutic Area : Dermatology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Cosmo Announces Submission of Winlevi® to the European Medicines Agency (EMA)
Details : Winlevi (clascoterone) cream is an androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age & older.
Product Name : Winlevi
Product Type : Small molecule
Upfront Cash : Not Applicable
October 10, 2023
Lead Product(s) : Clascoterone
Therapeutic Area : Dermatology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Clascoterone
Therapeutic Area : Dermatology
Study Phase : Approved
Sponsor : Hikma Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Cosmo and Hikma Sign License for Winlevi® in 17 Middle East and North Africa Countries
Details : Under the terms of the agreement, Hikma will receive from Cosmo, the exclusive right to register and commercialize Winlevi (clascoterone) in African countries, which is indicated for acne vulgaris.
Product Name : Winlevi
Product Type : Small molecule
Upfront Cash : $0.7 million
October 02, 2023
Lead Product(s) : Clascoterone
Therapeutic Area : Dermatology
Highest Development Status : Approved
Sponsor : Hikma Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Clascoterone
Therapeutic Area : Dermatology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Sun Pharma Canada Launches Prwinlevi for Treatment for Acne
Details : Winlevi (clascoterone) cream 1% is an androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.
Product Name : Winlevi
Product Type : Small molecule
Upfront Cash : Not Applicable
September 28, 2023
Lead Product(s) : Clascoterone
Therapeutic Area : Dermatology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Clascoterone
Therapeutic Area : Dermatology
Study Phase : Approved
Sponsor : Glenmark Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreements, Glenmark will receive from Cassiopea, the exclusive right to commercialize Winlevi (clascoterone cream), used on the skin (topical) to treat acne vulgaris in people 12 years of age and older, in 15 EU countries as well as in South A...
Product Name : Winlevi
Product Type : Small molecule
Upfront Cash : $5.0 million
September 27, 2023
Lead Product(s) : Clascoterone
Therapeutic Area : Dermatology
Highest Development Status : Approved
Sponsor : Glenmark Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Clascoterone
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Cosmo Begins Phase III Trials for Androgenetic Alopecia in Males
Details : CB-03-01 (clascoterone) solution is an androgen receptor inhibitor which is currently being evaluated for the treatment of patients with androgenetic alopecia.
Product Name : Winlevi
Product Type : Small molecule
Upfront Cash : Not Applicable
June 29, 2023
Lead Product(s) : Clascoterone
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Clascoterone
Therapeutic Area : Dermatology
Study Phase : Approved
Sponsor : Hyundai Pharm
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Cosmo and Hyundai Pharm Announce Signing of License Agreement for Winlevi® in Korea
Details : Under the license agreement terms, Hyundai Pharm will receive from Cosmo, the exclusive right to commercialize Winlevi (clascoterone) in the Republic of Korea, which is indicated for acne vulgaris.
Product Name : Winlevi
Product Type : Small molecule
Upfront Cash : Undisclosed
June 22, 2023
Lead Product(s) : Clascoterone
Therapeutic Area : Dermatology
Highest Development Status : Approved
Sponsor : Hyundai Pharm
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Clascoterone
Therapeutic Area : Dermatology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Sun Pharma Announces Health Canada Approval for PRWINLEVI® in Acne Treatment
Details : Winlevi (clascoterone) cream is an androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age & older.
Product Name : Winlevi
Product Type : Small molecule
Upfront Cash : Not Applicable
June 19, 2023
Lead Product(s) : Clascoterone
Therapeutic Area : Dermatology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Clascoterone
Therapeutic Area : Dermatology
Study Phase : Approved
Sponsor : Hyphens Pharma
Deal Size : $5.0 million
Deal Type : Licensing Agreement
Cosmo and Hyphens Announce Signing of License and Supply Agreements for Winlevi® in Southeast Asia
Details : WINLEVI (clascoterone) cream 1% is an androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.
Product Name : Winlevi
Product Type : Small molecule
Upfront Cash : $1.0 million
December 21, 2022
Lead Product(s) : Clascoterone
Therapeutic Area : Dermatology
Highest Development Status : Approved
Sponsor : Hyphens Pharma
Deal Size : $5.0 million
Deal Type : Licensing Agreement